HYDRO-RESERP
Clinical safety rating
cautionComprehensive clinical and safety monograph for HYDRO-RESERP (HYDRO-RESERP).
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
| Metabolism | Hydrochlorothiazide is not extensively metabolized; it is excreted unchanged in urine. Reserpine is extensively metabolized in the liver by hydrolysis and conjugation. |
| Excretion | Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites. |
| Half-life | 50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing. |
| Protein binding | 96% bound to albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | 1.5-2.5 L/kg; extensive tissue distribution with high affinity for adrenergic neurons. |
| Bioavailability | Oral: 50-60% (first-pass metabolism); IM: ~100%. |
| Onset of Action | Oral: 3-6 days; IM: 2-4 hours; IV: 30-60 minutes. |
| Duration of Action | Oral: 1-6 weeks after discontinuation due to irreversible binding to adrenergic vesicles; IM/IV: 4-12 hours. |
| Molecular Weight | 608.68 |
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR <30 mL/min/1.73m² due to HCTZ ineffectiveness. For GFR 30-50 mL/min: reduce HCTZ to 12.5-25 mg daily; reserpine unchanged. Monitor serum creatinine and electrolytes. Not recommended for anuric patients. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce HCTZ by 25-50% (start at 12.5 mg) due to risk of electrolyte imbalance; reserpine: use lowest effective dose (0.125 mg) and monitor for encephalopathy. Child-Pugh C: avoid HCTZ; reserpine contraindicated due to risk of hepatic coma. |
| Pediatric use | Not approved for pediatric use. Limited data: HCTZ 1-2 mg/kg/day orally once or divided; max 50 mg/day. Reserpine 0.01-0.02 mg/kg/day in 1-2 doses; max 0.25 mg/day. Monitor growth, electrolytes, and blood pressure closely in children. |
| Geriatric use | Start at half the adult dose: HCTZ 12.5 mg orally daily; reserpine 0.05-0.1 mg daily. Titrate slowly (every 2-4 weeks). Monitor for orthostatic hypotension, electrolyte disturbances, depression (reserpine), and dehydration. Avoid in frail elderly due to increased fall risk. |
| 1st trimester | Avoid due to risk of fetal abnormalities and decreased placental perfusion. |
| 2nd trimester | Avoid; may cause fetal hypotension, hypoxia, and thrombocytopenia. |
| 3rd trimester | Avoid; risk of neonatal hypotension, bradycardia, and hypothermia. |
Clinical note
Comprehensive clinical and safety monograph for HYDRO-RESERP (HYDRO-RESERP).
| Placental transfer | Reserpine crosses the placenta and can achieve fetal serum concentrations similar to maternal levels. |
| Breastfeeding | Reserpine is excreted into breast milk and may cause adverse effects in nursing infants, including nasal congestion, lethargy, and respiratory depression. Use is not recommended. |
| Lactation Rating | L5 (Avoid) |
| Teratogenic Risk | Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion. Avoid in preeclampsia due to risk of placental hypoperfusion. Risk category C. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate regularly. Fetal: assess heart rate and growth via ultrasound. Neonatal: observe for bradycardia, respiratory depression, and nasal congestion for 24-48 hours after delivery. |
| Fertility Effects | Reserpine may impair male fertility due to decreased libido and ejaculatory dysfunction. Female fertility may be affected by menstrual irregularities or galactorrhea. Reversible upon discontinuation. |
■ FDA Black Box Warning
Reserpine may cause mental depression, especially in patients with a history of depression. Risks are dose-related and may persist after discontinuation. Use with caution or avoid in patients with a history of depression.
| Serious Effects |
Known hypersensitivity to reserpine or any component of the formulationHistory of mental depression (especially with suicidal tendencies)Active peptic ulcerUlcerative colitisElectroconvulsive therapy (ECT) within 7 days
| Precautions | May cause depression with suicidal risk (reserpine)., May cause electrolyte imbalances (hypokalemia, hyponatremia) due to hydrochlorothiazide., May increase serum uric acid and precipitate gout., May cause orthostatic hypotension and bradycardia., Use cautiously in patients with renal impairment or hepatic disease. |
| Food/Dietary | Avoid high-sodium foods to reduce blood pressure; limit alcohol consumption. Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented foods) as reserpine may potentiate pressor response; however, risk is low with reserpine compared to MAOIs. Maintain potassium-rich diet if hypokalemia risk exists (e.g., bananas, oranges, spinach). |
| Clinical Pearls | Hydro-Reserp combines hydrochlorothiazide and reserpine; reserpine depletes catecholamines, which may cause depression and sedation. Monitor for orthostatic hypotension and electrolyte imbalances. Avoid in patients with history of depression or peptic ulcer disease. Use with caution in patients with renal impairment. |
| Patient Advice | Take this medication exactly as prescribed; do not stop abruptly. · May cause drowsiness or dizziness; avoid driving or operating machinery if affected. · Stand up slowly from sitting or lying down to prevent falls. · Report any signs of depression, unusual mood changes, or slow heartbeat. · Avoid excessive sun exposure; may increase sensitivity to sunlight. · Do not use alcohol while taking this medication. · Monitor blood pressure regularly and keep follow-up appointments. |
Loading safety data…